The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
New NPS Challenge Aims to Rewrite How the Military Builds Missiles
Officials say focusing on design methods, not hardware, could unlock fast, low‑cost manufacturing for future munitions.
11m watch -
The Value of ‘Pause, Breathe, Summarize’ in Cyber Leadership
A simple framework for clarity when everything feels urgent.
25m listen -
NIST Explains What’s Next for Federal AI Standards
NIST’s Martin Stanley outlines how AI control overlays, risk frameworks and future guidance will support agencies scaling AI systems.
6m watch -
CISA CIO on Agentic AI, Building the Cyber Workforce
Bob Costello discusses deploying agentic AI, speeding cyber approvals and strengthening the federal cybersecurity talent pipeline.
9m watch
